Actavis Standard Transcends Cash Deals, FTC Tells 3rd Circ.

Law360, New York (April 29, 2014, 3:21 PM EDT) -- The Federal Trade Commission on Monday urged the Third Circuit to revive a proposed antitrust class action against GlaxoSmithKline LLC and Teva Pharmaceutical Industries Ltd. over a deal to postpone generics of epilepsy drug Lamictal, arguing that cash isn’t the only form of compensation prohibited under a recent U.S. Supreme Court ruling on pay-for-delay agreements.

In an amicus brief filed with the appeals court, the FTC said a district judge got it wrong when he found that the high court's landmark decision in Federal Trade Commission...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.